March 11, 2005 -- The U.S. Food and Drug Administration (FDA) has warned healthcare professionals and patients via public health advisory of the potential cancer risk associated with use of ...

Two eczema creams — Novartis AG’s Elidel and Fujisawa Healthcare, Inc.’s Protopic, must carry a strong warning of cancer risk, the Food and Drug Administration said Thursday. Limited time: Save 25% on ...

Glenmark has received permission from the Food and Drug Administration for Tacrolimus Ointment, 0.03%, the generic of Leo Pharma's Protopic. Protopic Ointment, both 0.03% and 0.1% for adults, and only ...

July 23, 2007 (Chicago) — Children with moderate or severe atopic dermatitis can be treated less expensively over 6 weeks with 0.1% tacrolimus ointment than with 1% pimecrolimus cream, according to a ...

Two relatively new and very popular prescription creams used to treat eczema (search) in children and adults may soon carry a "black box" warning — indicating the drugs represent a cancer risk for ...

Glenmark Pharmaceuticals’ generic Protopic Ointment (tacrolimus ointment, 0.1% has received approval from the Food and Drug Administration. The drug is indicated to treat moderate-to-severe atopic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2006, when the FDA instilled black box warnings on ...

Astellas, an American a Japanese drug company, is suing a medical journal in Paris in part because it used a cartoon of a man in a silly hat to criticize one of its drugs, the eczma skin cream ...

Perrigo announced the availability of Tacrolimus Ointment, the generic version of Astellas’ Protopic Ointment. Protopic is an immunomodulator that is indicated as second-line therapy for short-term ...

Protopic, the topical formulation of Astellas’ tacrolimus, has been launched in Europe for a new indication – as maintenance treatment to prevent flares and prolong flare-free intervals in adults and ...

Astellas Pharma will sell its global dermatology business to LEO Pharma for €675 million ($724.7 million), a year after the seller lost U.S. patent exclusivity on its top skincare drug. LEO Pharma ...